Trifluoroacetic acid → HCID 71279506, compound

HRID 246428Notes

Reaction equation

HRID 246428 reaction equation
[C:1]([NH:5][C:6]([C:8]1[C:16]2[C:11](=[N:12][CH:13]=[C:14]([C:17]3[C:25]4[C:20](=[CH:21][CH:22]=[C:23]([O:26][CH:27]([F:29])[F:28])[CH:24]=4)[N:19]([CH2:30][CH2:31][CH2:32][N:33]4[CH2:36][CH:35]([OH:37])[CH2:34]4)[N:18]=3)[N:15]=2)[N:10](COCC[Si](C)(C)C)[CH:9]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2].C(O)(C(F)(F)F)=O>ClCCl>[C:1]([NH:5][C:6]([C:8]1[C:16]2[C:11](=[N:12][CH:13]=[C:14]([C:17]3[C:25]4[C:20](=[CH:21][CH:22]=[C:23]([O:26][CH:27]([F:28])[F:29])[CH:24]=4)[N:19]([CH2:30][CH2:31][CH2:32][N:33]4[CH2:36][CH:35]([OH:37])[CH2:34]4)[N:18]=3)[N:15]=2)[NH:10][CH:9]=1)=[O:7])([CH3:4])([CH3:2])[CH3:3]

Participants

4

Reactant 2

HCID 6422Trifluoroacetic acidHCID 71280909HCID 71280909, compound

Product 1

HCID 71279506HCID 71279506, compoundYield 61.2%

Reagents, catalysts & solvents 1

HCID 6344DichloromethaneSolvent

Conditions

Temperature
25 °C

Procedure

To a pale yellow solution of N-tert-butyl-2-(5-(difluoromethoxy)-1-(3-(3-hydroxyazetidin-1-yl)propyl)-1H-indazol-3-yl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (43 mg, 66.8 μmol) in dichloromethane (4.00 mL) was added TFA (740 mg, 0.5 mL, 6.49 mmol, Eq: 97.2), the reaction mixture turned orange and was stirred at 25° C. for 18 h, mixture concentrated and the residue was re-dissolved in 5 mL of a solution of (dichloromethane/MeOH/ammonium hydroxide; 60:10:1) and stirred at 25° C. for 1 h, then evaporated to a yellow foam, which was dissolved in dichloromethane (with few drops of MeOH) and purified by chromatography (spherical silica 20-45 μm, 23 g, Versaflash Supelco) eluting with 0 to 10% over 20 min (MeOH containing 10% ammonium hydroxide)/dichloromethane. The pure product dissolved in dichloromethane and cyclohexane added to allow solid formation, off-white solid was separated by decantation and dried under high vacuum to give N-tert-butyl-2-(5-(difluoromethoxy)-1-(3-(3-hydroxyazetidin-1-yl)propyl)-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (21 mg, 40.9 μmol, 61.2%). MS (M+H)+=514; 1H NMR (DMSO-d6) δ: 9.06 (s, 1H), 8.37 (s, 1H), 8.19 (s, 1H), 7.81-7.91 (m, 2H), 7.39 (d, J=8.7 Hz, 1H), 7.19 (t, J=74.4 Hz, 1H), 5.23 (d, J=6.4 Hz, 1H), 4.53 (t, J=6.6 Hz, 2H), 4.07-4.25 (m, 1H), 3.50 (t, J=6.4 Hz, 2H), 2.62 (t, J=6.8 Hz, 2H), 2.35 (t, J=6.8 Hz, 2H), 1.78-2.01 (m, 2H), 1.49 (s, 9H).

Workup

  1. concentrationmixture concentrated
  2. dissolutionthe residue was re-dissolved in 5 mL of a solution of (dichloromethane/MeOH/ammonium hydroxide; 60:10:1)
  3. stirringstirred at 25° C. for 1 h
  4. customevaporated to a yellow foam, which
  5. dissolutionwas dissolved in dichloromethane (with few drops of MeOH)
  6. custompurified by chromatography (spherical silica 20-45 μm, 23 g, Versaflash Supelco)
  7. washeluting with 0 to 10% over 20 min (MeOH containing 10% ammonium hydroxide)/dichloromethane
  8. dissolutionThe pure product dissolved in dichloromethane
  9. additioncyclohexane added
  10. customwas separated by decantation
  11. customdried under high vacuum

Sources & evidence

ORD record
ord-7ab36f16b93c4cb1adc4954ada187c91
Source dataset
uspto-grants-2014_02
Patent number
US08658646B2

Reaction notes

Loading…